Business
GenSight Biologics Announces Closing of Fundraising Worth Nearly EUR 3.7 Million
PARIS, October 01, 2025--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA
About this update from Gensight Biologics Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/c85da7a08a98f0ffc1cdfa40649a2cfc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jkKhb0dcsxxuowjobbFvjQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c85da7a08a98f0ffc1cdfa40649a2cfc","width":480,"height":204}},"lazy":false},{"type":"text","content":"PARIS, October 01, 2025--(BUSINESS WIRE)--Regulatory News:","length":58,"tagName":"p"},{"type":"text","content":"NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA","length":120,"tagName":"p","attribs":{}},{"type":"text","content":"GenSight Biologics (the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the closing of its EUR 3,694,665.92 fundraising (the "Fundraising").","length":361,"tagName":"p"},{"type":"text","content":"The Fundraising resulted in the issuance of:","length":44,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"18,816,666 ordinary shares of the Company (the "Offered Shares"), which were admitted to trading on Euronext Paris on September 30, 2025 (ISIN FR0013183985/SIGHT);","length":173,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"13,060,600 pre-funded warrants (the "Offered Pre-Funded Warrants") giving the right to subscribe to 13,060,600 additional ordinary shares (the "Pre-Funded Warrant Shares"); and","length":196,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"31,877,266 warrants (the "Offered Investor Warrants") giving the right to subscribe to 31,877,266 additional ordinary shares (the "Investor Warrant Shares").","length":177,"tagName":"p","attribs":{}}]}],"tagName":"ol","bulletedList":false,"length":546},{"type":"text","content":"The Offered Investor Warrants were admitted to trading on the Euronext Growth market in Paris ("Euronext Growth Paris") on September 30, 2025 (ISIN FR0014010IB4/SIGBS). The Offer...